Affimer® technology

Next-generation biotherapeutics to surpass the limitations of cancer therapies

Avacta’s proprietary Affimer® technology is a novel class of biological, based on the naturally occurring human protein Stefin A, which enables the development of next-generation biotherapeutics.

Affimer® proteins are smaller than antibodies meaning that they potentially have better tissue penetration advantages in solid tumours. This, combined with exquisite specificity, strong stability and high expression, confers excellent drug-like properties to Affimer® molecules.

The PK/PD of therapeutic Affimer® molecules can be tuned using Affimer XT®, a serum albumin-binding Affimer® with half-life extension properties, or using Affimer-Fc fusions. Affimer® molecules can also be genetically fused to each other to form multi-specific therapies, or to other proteins, such as the C-terminus of an antibody, to generate bispecific biobetter formats.

The Affimer® platform at a glance


Key advantages

  • Affimer® proteins can be made to be exquisitely specific.
  • Affimer® proteins can be generated to bind to targets that have proven very difficult for antibodies.
  • Affimer® proteins can be linked to create multi-specific therapeutics that address more than one target.
  • Affimer® proteins have excellent properties for drug development
    • They can quickly be generated to bind to a target of interest
    • They have a tuneable serum half-life
    • They are relatively cheap to manufacture
    • They are robust, stable and highly soluble
    • They have no post-translational modifications
    • The core Affimer® protein is human and therefore the risk of immunogenicity is lowered

Connect with us

Get in touch to discover our therapeutic technology platforms.

Read more

Partner with us

Get in touch to discuss partnering opportunities.

Read more

Request a meeting

Contact us to request a meeting.

Read more